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Abstract  
Atherosclerosis is considered an inflammatory disease, accordingly, there has been extensive 
research to determine whether microbial infections possibly contribute and maintain this 
inflammatory response. Chlamydia pneumoniae (C. pneumoniae), a common causative agent 
of respiratory tract infections, was associated with coronary artery disease (CAD) diseases. C. 
pneumoniae is a gram-negative bacterium which resembles viruses in terms of obligate 
intracellular growth. C. pneumoniae is able to infect several cell types, including circulatory 
monocytes, and by using monocytes as a vector, C. pneumoniae can disseminate from the 
lungs into extrapulmonary sites, including the subendothelium space of the arterial wall. In 
addition to inflammation lesion, development in the arterial wall requires macrophage 
transformation foam cells in the presence of an atherogenic cholesterol source like low-
density lipoprotein (LDL) cholesterol.  
The present investigation studied the relationship and prevalence of C. pneumoniae in patient 
with CAD who underwent to angiography.  In this study, 130 patients were enrolled. Blood 
samples were taken from each patient, data collection, ELISA for IgG antibody and PCR for 
OMP1 gene have been carried out. The results showed that the prevalence of C. pneumoniae 
among the study sample was 56 out of 130 (43.1%) when ELISA is applied. However, 
prevalence of C.  Pneumoniae decreased to 36 samples (27.7%) when the previous results 
were confirmed using PCR. This indicates that 65% of the ELISA positive samples were also 
PCR positive. The patients with CAD were considered as clinical symptomatic for C.  
pneumoniae, indicated that the organism used monocytes and macrophages as a vector, which 
lead to the acceleration of the atherosclerosis process. The total number of the patients, who 
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did not have any risk factor were 28 out of 130 patients (21.5 %). Twenty samples out of 
these 28 were positive in both ELISA and PCR (71.4 %),4 samples were positive in ELISA 
and negative in PCR(14.3 % ), and 4 samples were negative in both ELISA and PCR 
(14.3%).  
C. pneumoniae infection is considered as independent risk factor for CAD or atherosclerosis 
process. This study showed that there is an association between C.  pneumoniae and CAD, 
between C. pneumoniae and diabetes, hypertension and smoking. On the other hand, it was 
clear that there is no association between C. pneumoniae and age, sex, living area, residence 
area, job, health food, rest pain, intermittent claudicating, obesity, hyperlipidemia, and 
environmental exposure. 
Keywords: C. pneumoniae, Coronary Artery Disease (CAD), diabetes  
 
Introduction  
Chlamydia pneumoniae is a gram negative bacterium which resembles viruses in 
terms of obligate intracellular growth, which belongs to Chlamidiaceae. It is considered as a 
common cause of pneumonia. A third species of the genus Chlamydia causes acute 
respiratory disease and has been implicated on the basis of serological assay, as a cause of 
bronchitis, sinusitis and acute chest syndrome of sickle cell disease as well as asthma 
(Campbell et al.,1992). Furthermore, C. pneumoniae has been implicated as an inflammatory 
agent in atherosclerosis, a disease in which plaque builds up on the insides of arteries.  Plaque 
is made up of fat, cholesterol, calcium, and other substances found in the blood.  Over time, 
plaque hardens and narrows the arteries and the flow of oxygen-rich blood to organs and 
other parts of the body is reduced.  This can lead to serious problems, including heart attack, 
stroke, or even death (Saikku, 2000; Kalayoglu, Libby and Byrne, 2002; Watson and Alp, 
2008).                                                               . 
Development of foam cells from macrophages is a feature of atherogenesis. In vitro 
studies found that exposure of human macrophages to a combination of C. pneumoniae and 
LDL induced their transformation into foam cells (Wissler. 1995; Leinonen and Saikku. 
1999). C. pneumoniae infection is ubiquitous and asymptomatic. Reinfection occurs 
commonly and antibodies against C. pneumonia are rare in children under the age of 5. 
Except in developing and tropical countries, approximately 50% of adults world wide have 
antibodies against C. pneumoniae and continues to increase slowly to 70% to 80% at ages 60 
to 70 (Kuo, et al. 1995), and up to 10% of pneumonia patients were found infected with C. 
pneumoniae (Marrie, et al .1987; Grayston, et al .1986; Wang and Graystone, 1990). Patients 
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with coronary artery disease are significantly more likely to have serological evidence of past 
infection with C. pneumoniae (Saikku, et al. 1988; Saikku, et al 1992).                                                                                                          
Diagnosis of C. pneumoniae infection is based on PCR assay, in which primers 
specific for C. pneumoniae are used. The nucleic acid sequence of the OMP1 of C. 
pneumoniae was determined (Moazed, et al. 1998).                                                             
The epidemiological infection of C. pneumoniae has been derived from serological 
studies using the C. pneumoniae specific microimmunofluorescence test (Kuo, et al. 1995). 
The expanding spectrum of C. pneumoniae infection has been related to clinical 
manifestation such as carotid artery stenosis, aortic aneurysm, cloudication, and stroke 
(Muhlestein, et al. 1999), and has been associated with other acute and chronic respiratory 
diseases as well as other clinical syndromes including erythema, nodosume, reiter syndrome, 
and sarcoidosis (Kuo, et al. 1995). These were determined by isolation or detection of the 
organism in specimen and seroepidimiological observation or combination of these methods 
(Molestina, et al. 1998). Immune complexes containing C. pneumoniae lipopolysaccharide 
have also been associated with 42 and 98 KDa C. pneumonia-specific antigens (Linnanm, et 
al. 1993); these associations have been extended to carotid artery disease and cerebrovascular 
disease (Danesh and Collins. 1997). C. pneumoniae antibodies have been associated with 
CAD and cerebrovascular disease, most were statistically significant, and the risk is 
independent of other CAD risk factors (hypercholesterolaemia, smoking, hypertension, 
diabetes, and family history). 
Compelling evidence of the association of C. pneumoniae and atherosclerosis has 
been obtained by PCR, immunocytochemistry staining and electron microscopy, which have 
detected C. pneumoniae in atheromatuos lesion (Juvonen, et al.  1997). 
 Structures found within coronary atheromas were remarkably similar to the pear-
shaped elementary body morphological characteristics described for C. pneumoniae 
(Grayston, et al. 1995). 
The organism was found in tissues of male and female study participants of different 
ages and ethnic groups (Blasi, et al. 1996). This finding was confirmed by other 
investigations and also has found the organism in atherosclerotic lesion in iliac arteries and 
tissues from abdominal aortic aneurysms and aortic valve stenosis (Maass, et al. 1997; Jang, 
et al. 1993; Linnanm, et al.1993). 
Other infectious agents including herpes simplex virus (HSV), cytomegalovirus 
(CMV), and Helicobacter pylori have been associated with cardiovascular disease. Only a 
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few studies have concurrently investigated the presence of C. pneumoniae and these 
infectious agents within lesion (Chiu, et al. 1997). 
In a study investigating the presence of C. pneumoniae, CMV, and HSV in 
atherosclerosis and carotid artery, C. pneumoniae was also detected more frequently (71%) 
than CMV and HSV (35% and 10%, respectively) (Ong, et al. 1996). C. pneumoniae and 
CMV were independently associated with an increased risk for thrombosis (Chiu, et al. 
1997). 
  Although C. pneumoniae and HSV or CMV may be found in the same lesion, C. 
pneumoniae has been more frequently found as the only infectious agent (Ong, et al. 1996). 
The biological role of C. pneumoniae in atherogenesis was demonstrated by the 
presence of the organism. Three possibilities can be examined, first; the organism persist in 
vascular cells but does not contribute to pathologic abnormality, second; causes the initial 
injury and induces the atherosclerosis process, third; accelerates the severity or progression of 
the disease. If C. pneumoniae is involved, endothelial injury or activation resulting in 
monocyte/ macrophages adherence to the endothelium, migration to subendothelium, uptake 
of oxidized low-density lipoproteins transforming them into foam cells, and releases of 
cytokines have been occurred. These cytokines upregulate endothelial cell adhesion 
molecules leading to increased leukocyte adhesion, platelet aggregation at the site of 
endothelial damage resulting in the release of platelet-derived growth factor. This stimulates 
smooth muscle cell proliferation. Dedifferentiation of smooth muscle cells, which secrete 
collagen, elastin, and proteoglycans leads to the formation of fibrous tissue. The mature 
fibrolipid plaque consists of a lipid / cholesterol-rich core surrounded by fibrous cap 
composed of matrix elements (Grnhagen-Riska, et al. 1988). 
Consistent with observations in animal models and humans, in vitro studies have 
demonstrated that vascular cells are susceptible to C. pneumoniae infection which produces 
productive infection in human macrophages, endothelial cells, and artery smooth muscle cells 
(Gaydos, 1996; Kalayoglu, 1998a). 
In vitro studies have also investigated whether infection leads to the production of 
immunomodulators (Kalayoglu, 1998b). Another investigation obtained by in vitro study 
addressing a potential role of C. pneumoniae in atherogenesis found that exposure of human 
monocyte-derived macrophages to C. pneumoniae followed by addition of low-density 
lipoprotein resulted in foam cell formation, accumulation of cholesteryl esters, which 
accelerates the atherosclerosis process (Kalayoglu, 1998). 
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The ability of C. pneumoniae infection to induce the production of proinflammatory 
and procoagulate activities was investigated to determine its putative role in eliciting immune 
responses consistent with atherosclerotic processes (Kaukoranta, et al. 1996; Fong, et al. 
1997). 
Etiology can be established only through animal models or intervention studies. 
Rabbit and mice are susceptible to C. pneumoniae infection and provide well-defined model 
of atherosclerosis. Respiratory disease in both species is characterized by multifocal 
interstitial pneumonia. The disease is more severe and longer lasting in mice, and organisms 
are reisolated more readily from the lungs and aorta (Laitinen, et al. 1997). Early studies in 
rabbit and mice models indicate that C. pneumoniae infection can induce inflammatory 
changes similar to those of atherogenesis and augment the progression of the atherosclerotic 
lesion (Moazed, et al. 1998). There are many experiments demonstrated that DNA from dead 
organism is rapidly degraded, whereas live organisms survive within macrophages (Fryer, et 
al. 1997). 
A causative role of C. pneumoniae infection in cardiovascular disease has not yet 
been firmly established, however, the high frequency of infection found in human 
atherosclerotic tissue in comparison to normal tissue, the induction and progression of 
atherosclerotic-like inflammatory changes in infected animal models of atherosclerosis, and 
early results from antichlamydial intervention studies in human are consistent with a 
causative role of C. pneumoniae in the disease process (Kim, et al. 2008). 
C. pneumoniae was distinct from other two Chlamydial species that infect human, 
namely C. trachomatis and C. psittaci, this was clear by investigation of their diversity and 
immunoblot assay (Graystone, et al. 1975; Carter, et al. 1991). 
Other studies indicated that there is an evidence for a relationship between coronary 
artery disease and C. pneumoniae .However, this issue needs more investigation (Danesh, and 
Collins, 1997). 
Study objectives 
 1- To investigate the relationship between C.  Pneumoniae and CAD patients in the 
Northern Jordan. 
 2- To study the prevalence of C. pneumoniae within the patient with CAD in the 
Northern Jordan. 
Methods and subjects  
 Sample collection: venous blood was collected from patients of the cardiology clinic 
who underwent angiography in the king Abdullah University Hospital. Sex, age, and 
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diagnosis of each donor were recorded at the time of initial blood withdrawal. One hundred 
and thirty patients with cardiovascular disease were enrolled in this study. The control group 
was represented by 50 healthy donors. 
 As shown in (Table 1), there are 180 participants in this study among them 130 
patients with CAD and 50 participants as control (no apparent health problems were noted or 
reported). Out of the CAD patients there were 48 female and 82 male participants. The mean 
age of the patients is 51 years. All patients are Jordanians. Living areas for patients included: 
city (57), villages (62) and desert (11) participants. The patients were coming from different 
cities in the north of Jordan among which are: Irbid 42 participants, Jerash 20, Ajloun 15, 
Mafraq 12 and others 41. Exercise training was performed by 78 patients while 52 patients 
did not. Regarding the control group, there were 10 females and 40 males. The mean age was 
42 years. All control patients are Jordanians. Control participants live in: city (17), village 
(30) and desert (3) participants. Residence areas included: 36 participants in Irbid, 4 from 
Jerash, 2 from Ajloun and 8 from Mafraqe. Concerning the control group, 17 participants 
reported exercise training while 33 participants did not report exercise training.  
Table 1:- Demographic characteristic of the study population: 
Percent (%)   Frequency(No) 
 
 
Variables 
 Control Patients Control 
(50) 
Patients 
 )130(  
 
 
80 
20 
 
 
63 
37 
 
 
40 
10 
 
 
82 
48 
 
Sex: 
 
Male 
Female 
 
 
34 
60 
6 
 
43.8 
47.7 
8.5 
 
17 
30 
3 
 
57 
62 
11 
 
Living area: 
City 
Village 
Desert 
 
 
72 
8 
4 
16 
0.00 
 
 
32.3 
15.4 
11.5 
9.2 
31.5 
 
 
36 
4 
2 
8 
0.00 
 
 
42 
20 
15 
12 
41 
Residence area: 
Irbid 
Jerash 
Ajloun 
Mafraqe 
Others 
 
 
34 
66 
 
 
 
 
60 
40 
 
 
17 
33 
 
 
78 
52 
Exercise activity: 
Yes 
No 
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PCR of blood mononuclear cells  
 EDTA blood was collected from the patients with coronary artery disease. Samples 
were stored overnight at 4ºC for the processing next day. 
 The plasma was clarified by centrifugation and the supernatant was stored at -27 ºC 
for serology. Blood cells were layered onto 3 ml of lymphoprep .The mononuclear cell layer, 
which also contained platelets was collected after centrifugation at 500 g for 15 min, washed 
twice in PBS and stored at -27 ºC. DNA was prepared according to Tong and Cillis (1993) 
from the blood mononuclear cells. The method implies addition of 8ml ice-cold cell lysis 
buffer to each 2 ml of blood. The mixture was then vortexed well and centrifuged for 10 min 
at 4000 rpm and 4ºC. The supernatant was separated carefully. This step was repeated. Eight 
ml of ice-cold pellet lysis buffer were added to each pellet, vortexed and centrifuged for 10 
min. at 4000 rpm at 20 ºC. Then the supernatant was carefully taken. This step was also 
repeated again. Then 3 ml of nuclei lysis buffer, 120μl of proteinase K, 200μl of 10% SDS 
were added and the samples were incubated at 37ºC overnight. After the incubation period 
1ml of the saturated NaCl solution was added and shaked vigorously for 20 sec and then 
centrifuged for 20 min. at 4000 rpm at 20 ºC. The supernatant was removed into a clean tube. 
Two volumes of ice-cold of absolute ethanol were then added to the supernatant and the vial 
was inverted several times. The DNA strands were removed into a clean 1.5 ml tube 
containing 500μl of 70 % ethanol, and centrifuged for 5 min at 7000 rpm at 20ºC. The pellet 
was taken after decanting the supernatant and was left to dry at room temperature and 
resuspended in 200 µl of DNA rehydration buffer for 2 hrs at room temperature and stored at 
-20ºC. 
 The following PCR programme was used; denaturation at 94ºC for 30 sec. primer 
annealing at 58ºC for 1.5 min, and extension at 72ºC for 1 min, followed by 45 cycles. 
 The following were added to the PCR tubes (treated sample and control sample): 
• 12.5 µl master mix (master mix contains 20mM Tris HCl, pH   8.3, 1.5 mM 
magnesium chloride, 25mM potassium chloride, 50µM of each of the 
deoxynucleodise triphosphate (dATP, dCTP, dGTP, dTTP), 2 units Taq DNA 
polymerase) 
• 1.3 µl OMP1 primer sense (Table 2). 
• 1.3 µl OMP1 primer antisense (Table 2). 
• 7.9 µl nuclease free water. 
• 2 µl DNA sample. 
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 PCR was performed using 3μl DNA solution. The amplification of OMP1 gene were 
carried out and the products were visualized by electrophoresis on 2% agarose gel 
electrophoresis, stained with ethidium bromide, and monitored using UV-transeluminator.  
 
Table 2: The primer pair sequences that were used to amplify in this study: 
Primer Sequence Size of fragment (bp) 
omp1  207 
  Sense 5'-TTA TTA ATT GAT GGT ACA ATA-3' 
  Antisense 5'-ATC TAC GGC AGT AGT ATA GTT-3' 
 
 
Enzyme –linked immunosorbent assay (ELISA) 
 C. pneumoniae-specific IgG antibody was detected by an rDNA lipopolysaccharide 
ELISA. This ELISA includes a chemically pure structure of a recombinant LPS, which 
contains a genus-specific epitope of the C.  Pneumoniae. Microtiter plate wells are coated 
with C. pneumoniae antigens to bind corresponding antibodies of the specimens. After 
washing the wells to remove all unbound molecules, sample material (HRP) labeled anti-
human IgG conjugate is added. This conjugate binds to the captured C. pneumoniae-specific 
antibodies. The immune complex formed by the bound conjugate is visualized by adding 
tetramethylbenzidine (TMB), substrate which gives a blue reaction product. The intensity of 
this product is proportional to the amount of C. pneumoniae-specific IgG antibodies in the 
specimen.  
 Sulphuric acid is added to stop the reaction. This produces a yellow end point color. 
Absorbance at 450nm is read using an ELISA microwell plate reader. (ELISA Fx10, made in 
USA) 
Materials: kit (Nova Tec Immunodiagnostica GmbH) 
Reagents 
• C. pneumoniae coated wells (IgG): 12 breakpart 8-well snap-off strips coated with C. 
pneumoniae antigen.  
• IgG sample diluents: buffer for sample dilution; PH 7.2±0. 
• Stop solution: 0.2 mol/1 of Sulphuric acid. 
• Washing solution: 20-fold concentrated buffer (PH 7.2±0.2) for washing the wells. 
• C. pneumoniae anti-IgG conjugate: (HRB) labeled rabbit antibody to human IgG. 
• C. pneumoniae IgG positive control 
• C. pneumoniae IgG negative control. 
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• C. pneumoniae IgG cutt-off control. 
Equipments 
• ELISA microwell plate reader, equipped for the measurement of absorbance 450/620 
nm (Kit from Nova Tec Immunodiagnostica GmbH). 
Reagent preparation 
• Solution with C. pneumoniae anti- IgG conjugate with horseradish peroxidase, buffer, 
stabilizers, preservatives and an inert red dye. 
• Controls: the bottles labeled with positive, negative, and cut-off controls contain a 
ready to use control solution, each contains 0.1% Kathon. 
• IgG sample diluents: contains phosphate buffer saline PH 7.3, stabilizers, preservative 
and an inert yellow dye, it is used for the dilution of the patient specimen. 
• Washing solution: concentrated buffer, detergent, and preservatives. 
• TMB substrate solution: contains tetramethylbenzidine/hydrogen peroxide system.   
• Stop solution: contains 0.2 mM Sulphuric acid solution. 
• Sample collection and preparation: serum samples were used with this assay. 
• Sample dilution: all samples were diluted 1:100 with IgG sample diluents.  
Assay procedure 
• 100µl controls and diluent's sample was dispensed into their respective wells. A1 
wells were left for substrate blank. 
• The wells were covered with the foil, and incubated for 1 hr at 37ºC. 
• After incubation, the foil was removed and the content of the wells was aspirated and 
each well was washed three times with 300µl of washing solution. 
• 100µl of C. pneumoniae anti-IgG conjugate was dispensed into all wells except for 
the blank well and the wells were covered with foil and incubated for 30 min at room 
temperature. 
• Washing of each well was repeated three times with 300µl of washing solution. 
• 100µl of TMB substrate solution was dispensed into all wells. 
• 100 µl of stop solution were dispensed into all wells. 
• The absorbance of the specimen at 450/620 nm was measured within 30 min after 
addition of the stop solution. 
Measurement  
 The ELISA microwell plate reader to zero was adjusted using the substrate blank 
well, then measured of all well at 450 nm; the absorbance value was recorded for each 
controls and patient sample. 
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Calculations 
 The cut-off is the mean absorbance value of the cut-off control determinations. 
 The cut-off results was (0.443/0.456) and the mean value of the cut- off control = 
0.443+0.456÷2= 0.452  
 The samples were considered positive if the absorbance value equal or greater than 
the mean of absorbance value of the cut-off controls, and the samples were considered 
negative if the absorbance was below the cutt –off mean absorbance value. 
Data analysis 
 SPSS program was used to explore association of the presence of C. pneumoniae 
DNA and conventional coronary risk factor with coronary artery disease of those subjects 
who does have coronary artery disease. 
Results 
CAD related factors 
In this section of the study, there was a strong tendency to examine if the heart related 
factors under study are of important risk factors that might be associated with the 
pathogenesis of C. pneumonia or CAD. However, the heart related factors under study 
included the following factors as shown in Table 3:  CAD symptoms, intermittent 
claudication, resting pain, heart problems, previous heart problems, brain problems, kidney 
problems, hypertension, diabetes, obesity, smoking, hyperlipidemia, environmental exposure 
and healthy food. 
Table 3:- CAD related factor among the study and control group 
Variable      Frequency (no)        Percent (%) 
Patients (130) Control  (50) Patients  Control  
CAD symptoms 
Yes 
No 
 
55 
75 
 
0.00 
50 
 
42.3 
57.7 
 
0.00 
100 
Intermittent Caudication 
Yes 
No 
 
 
50 
80 
 
 
4 
46 
 
 
38.5 
61.5 
 
 
8 
92 
Rest pain 
Yes 
No 
 
62 
68 
 
0.00 
50 
 
47.7 
52.3 
 
0.00 
100 
Heart problems 
Yes 
No 
 
34 
96 
 
0.00 
50 
 
26.2 
73.8 
 
0.00 
100 
Brain Problems 
Yes 
No 
 
15 
115 
 
1 
49 
 
11.5 
88.5 
 
2 
98 
kidney Problems 
Yes 
No 
 
2 
128 
 
1 
49 
 
1.5 
98.5 
 
2 
98 
Hypertension 
Yes 
No 
 
66 
64 
 
7 
43 
 
50.8 
49.2 
 
14 
86 
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Diabetes 
Yes 
No 
 
 
63 
67 
 
 
7 
43 
 
 
48.5 
51.5 
 
 
14 
86 
Obesity 
Yes 
No 
 
41 
89 
 
12 
38 
 
31.5 
68.5 
 
24 
76 
Smoking 
Yes 
No 
 
44 
86 
 
28 
22 
 
33.8 
66.2 
 
56 
44 
Hyperlipidemia 
Yes 
No 
 
50 
80 
 
15 
35 
 
38.5 
61.5 
 
30 
70 
Environmental Exposure 
Dust 
Chemical Materials 
Radiation 
Non of them 
 
 
37 
 
1 
0.00 
92 
 
 
13 
 
1 
 
0.00 
36 
 
 
28.5 
 
0.8 
 
0.00 
70.7 
 
 
26 
 
0.8 
 
0.00 
72 
Healthy Food 
Yes 
No 
 
78 
52 
 
35 
15 
 
60 
40 
 
70 
30 
Exercise activity 
Yes 
No 
 
 
78 
52 
 
 
17 
33 
 
 
60 
40 
 
 
34 
66 
Your home at 
City centre 
Village 
Desert 
Refugee camp 
 
 
57 
62 
 
11 
 
0.00 
 
 
17 
30 
 
3 
 
0.00 
 
 
 
43.8 
47.7 
 
8.5 
 
0.00 
 
 
34 
60 
 
6 
 
0.00 
 
ELISA results  
130 sample patients with coronary artery disease were diagnosed using IgG C. 
pneumoniae antibody, out of 130 patients, 56 were seropositive for C. pneumoniae (43.1 %). 
Six healthy donors out of 50 (control group) were seropositive for C. pneumoniae (12%). 
PCR results 
 Samples  of CAD who were positive for C. pneumoniae using the ELISA were tested 
for OMP1 gene using PCR. Figure 1 and 2 illustrate the results of agarose gel electrophoresis 
for the amplified product of OMP1 gene for 36 patients out of 130. PCR positivity for C. 
pneumoniae was higher in CAD patients 27.6% compared with healthy control (0.00%) and 
all 36 positive PCR were highly positive in ELISA, indicating an active infection for C 
pneumoniae. Baseline clinical characteristics age, sex, gender, job, residence, 
asymptomatology, intermittent cloudication, rest pain, heart disease, brain disease, kidney 
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problem, hypertension, diabetes, obesity, smoking, hyperlipidemia, exposing to, healthy food 
and home site were compared in  C. pneumoniae CAD patients and healthy control. No 
significant variation in positivity for  C. pneumoniae were observed between age, sex, job, 
residence, asymptomatology, intermittent cloudication, rest pain, heart disease, brain disease, 
kidney problem,  obesity, smoking, hyperlipidemia, exposing to, healthy food and home site. 
However, significant variations in positivity for C. pneumoniae between smoking, 
hypertension and diabetes were observed (tables 4-6). 
 
 
Figure 1: Agarose gel electrophoresis of PCR product of OMP1 gene (26 CAD samples).  
 
Lane 1 and 16 represent 100 bp DNA ladder, lane 2 and17 represent negative control, lane(3, 
4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30) 
represent samples No(7, 8, 9, 11, 12, 13, 14, 17, 19, 21, 24, 25, 30, 34, 35, 37, 41, 58, 59, 66, 
69, 71, 74, 75 and 83, respectively). 
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Figure 2: Agarose gel electrophoresis of PCR product of OMP1 gene (10 CAD samples):  
Lane 1 represent 100 bp DNA ladder, lane 2 represent negative control, lane (3, 4, 5, 6, 7, 8, 9,10, 
11and 12) represents samples No (86, 91,  99,  100, 102, 103, 105, 110, 112 and 122, respectively). 
 
Table 4:- Tests results of patients with CAD, with and without risk factors 
Test results of 
patients with 
CAD. 
Positive PCR Negative PCR  Positive PCR with 
risk factor 
Positive PCR 
without risk factor 
Positive ELISA 36 20 20 16 
Negative ELISA 0.00 74 0.00 0.00 
 
Table 5:- negative relationship between CAD/C. pneumoniae and Study variables 
Variables P value٭ 
Job and C. Pneumoniae 0.118 
Residence area and C. Pneumoniae 0.104 
Age and C. Pneumoniae 0.640 
Gender and C. Pneumoniae 0.583 
Environmental exposure and C. Pneumoniae 0.140 
Healthy food and C. Pneumoniae 0.450 
Living area and C. Pneumoniae 0.278 
Asymptomatology and C. Pneumoniae 0.431 
Intermittent claudication and C. Pneumoniae 0.317 
Rest pain and C. Pneumoniae 0.119 
Heart problem and C. Pneumoniae 0.657 
Brain problem and C. Pneumoniae 0.721 
Kidney problem and C. Pneumoniae 0.521 
Obesity and C. Pneumoniae 0.657 
Hyperlipidemia and C. Pneumoniae 0.159 
٭ There is no significant association, P value > 0.05. 
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Table 6:- Positive relationship between CAD/C. pneumoniae and Variables 
Variables P value٭ 
Diabetes and C. pneumoniae 0.032 
Hypertension and C. pneumoniae 0.018 
Smoking and C. pneumoniae 0.003 
CAD and C. pneumoniae 0.001 
٭ There is a significant association, P value < 0.05 
Discussion 
The role of microbes in inducing diseases has already been established. With time, 
other nonclassical roles of pathogens have been reported. For example, the relationship 
between cancers and some viruses as the role of human papilloma virus (HPV) in causing 
cervical carcinoma (Parkin. 2006). Another association between gastric ulcer and 
Helicobacter Pylori has also been reported (Cullen, et al. 1997). A large number of studies 
have been reported on the association between the obligate intracellular bacterium, C. 
pneumoniae and atherosclerosis (Saikku, et al. 1992). 
In this study, other nonclassical role for C. pneumoniae with CAD was investigated to 
explore the relationship between C.  Pneumoniae and CAD patients in the northern Jordan 
and the prevalence of C. pneumoniae among patients with CAD in the northern Jordan. 
The results showed that the prevalence of C. pneumoniae among the study sample 
was 43.1% when ELISA was applied. The prevalence of C. pneumoniae decreased to 27.7% 
when the previous results were confirmed using PCR. Our findings are not consistent with 
other reported studies in literature. Hem, et al (2007) investigated the association between C. 
pneumoniae and CAD. The results of their study showed more positive results with PCR 
(29.6%) compared with the detection of circulating antibodies IgA and/or IgG (14%).  
George et al (2003) showed that out of 130 patients, only nine had viable C. pneumoniae in 
peripheral blood mononuclear cells (PBMCs) while 64 had serum IgG for C. pneumoniae. 
Although patients with atherosclerosis associated with C. pneumoniae had higher 
atherosclerotic scores, seropositive and negative patients showed similar scores. Patients with 
atherosclerosis exhibited higher inflammatory indices. Neither patients with detectable C. 
pneumoniae in PBMCs nor seropositive subjects had higher inflammation than negative 
patients. Melanie (2004) found that only two out of 43 (5%) patients with CAD had C. 
pneumoniae DNA presence within their peripheral blood mononuclear cell (PBMC) fraction 
using PCR analysis for OMP1 gene. Chlamydial antibodies were detected by ELISA. Also he 
showed that 95 % of the PCR positive patients exhibited positive IgG in ELISA test. In the 
present study 100 % of the PCR positive patients for C. pneumoniae OMP1 gene, were also 
IgG positive in ELISA test.  
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Our PCR results showed that 36 samples were positive for OMP1 specific C.  
pneumoniae (65%). These samples were also positive in ELISA test.  
The samples, which gave the IgG titer below 0.600 O.D in ELISA reading, did not 
give positive PCR 0.00%, while the samples, which showed negative PCR and positive 
ELISA may be considered as samples from patients with sub-clinical symptoms for C. 
pneumoniae according to O.D value (low positive). On the other hand, samples that were 
positive in both ELISA and PCR (above 0.613) were considered as samples from patient with 
chronic C.  pneumoniae infection.  
All negative ELISA samples for IgG antibodies for C. pneumoniae were also PCR 
negative. This result proved that when C.  pneumoniae was able to use macrophages and 
monocytes as dissemination vectors, the atherosclerosis process is accelerated. 
The total number of patients, who did not have any risk factor, were 28 out of 130 
patients (21.5 %). Twenty samples out of 28 were positive in both ELISA and PCR (71.4 %). 
Four samples from 28 samples were positive in ELISA and negative in PCR (14.3 %). Four 
samples from 28 samples were negative in both ELISA and PCR (14.3%).  
The Control group which was enrolled in this study consisted of 50 healthy donors, 10 
females and 40males. The mean age was 42 years, and they were subjected to the same 
protocol applied to the patients.  
In ELISA test, 56 samples of patients gave positive results for IgG antibodies and 6 
samples of the control group gave positive results in ELISA and the IgG titers were below 
0.600 O.D. This result was confirmed by PCR (amplification for OMP1 gene), in which all 
samples were PCR negative. The 6 samples out of 50 control group, which were positive in 
ELISA and negative PCR may be from patients who are sub-clinical symptomatic for C. 
pneumoniae infection.  
In our study, 36 sample out of 56 (65%) were ELISA positive and PCR positive, that 
indicates an active infection or clinical symptoms for C. pneumoniae infection, which may 
points to a participation in the atherosclerosis process. The results may reflect that clinical 
symptoms of infection appear when C. Pneumoniae is able to use the monocytes and 
macrophages as a vector for its dissemination. 
According to the results of the present investigation C. pneumoniae infection can be 
considered as independent risk factor for CAD or atherosclerosis process. There is an 
association between C.  pneumoniae and CAD, diabetes, smoking and hypertension. On the 
other hand, we found that there is no association between C. pneumonia and age, sex, living 
European Scientific Journal  February 2013 edition vol.9, No.6  ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
210 
 
area, residence area, job, health food, rest pain, intermittent cloudication, obesity, 
hyperlipidemia, and environmental exposure. 
Conclusions  
 1- Both PCR and ELISA tests for C.  pneumoniae indicated that there is a significant 
correlation with CAD. 
 2- According to our results and their statistical analysis C. pneumoniae is considered 
as an independent risk factor for CAD and atherosclerosis. 
 3- Presence of C.  pneumoniae DNA in peripheral blood mononuclear cells, means 
that this bacteria used the Mononuclear cells as a vector for the dissemination when the 
infection reaches at high level. 
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